Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 164
- Registration Number
- NCT01867710
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 148
- Registration Number
- NCT01858441
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 9
- Registration Number
- NCT01848067
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Abiraterone Acetate in Molecular Apocrine Breast Cancer
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 34
- Registration Number
- NCT01842321
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷Chu de Brest - Hôpital Morvan, Brest, France
🇫🇷Ico - Site Paul Papin, Angers, France
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT01834209
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 13
- Registration Number
- NCT01828476
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- British Columbia Cancer Agency
- Registration Number
- NCT01814865
- Locations
- 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦Segal Cancer Centre, Montreal, Quebec, Canada
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01795703
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01792687
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.